Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Decreased xanthine oxidoreductase (XOR) is associated with a worse prognosis in patients with serous ovarian carcinoma.

Linder N, Bützow R, Lassus H, Lundin M, Lundin J.

Gynecol Oncol. 2012 Feb;124(2):311-8. doi: 10.1016/j.ygyno.2011.10.026. Epub 2011 Oct 29.

PMID:
22044687
2.

Down-regulated xanthine oxidoreductase is a feature of aggressive breast cancer.

Linder N, Lundin J, Isola J, Lundin M, Raivio KO, Joensuu H.

Clin Cancer Res. 2005 Jun 15;11(12):4372-81.

3.

Xanthine oxidoreductase - clinical significance in colorectal cancer and in vitro expression of the protein in human colon cancer cells.

Linder N, Martelin E, Lundin M, Louhimo J, Nordling S, Haglund C, Lundin J.

Eur J Cancer. 2009 Mar;45(4):648-55. doi: 10.1016/j.ejca.2008.10.036. Epub 2008 Dec 26.

PMID:
19112016
4.

Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer.

Skírnisdóttir I, Seidal T.

Int J Gynecol Cancer. 2011 Aug;21(6):1024-31. doi: 10.1097/IGC.0b013e31821dc906.

PMID:
21792012
5.

Aurora-A overexpression and aneuploidy predict poor outcome in serous ovarian carcinoma.

Lassus H, Staff S, Leminen A, Isola J, Butzow R.

Gynecol Oncol. 2011 Jan;120(1):11-7. doi: 10.1016/j.ygyno.2010.09.003. Erratum in: Gynecol Oncol. 2012 Apr;125(1):282-3.

PMID:
20937525
6.

Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.

Høgdall EV, Christensen L, Høgdall CK, Blaakaer J, Gayther S, Jacobs IJ, Christensen IJ, Kjaer SK.

Oncol Rep. 2007 Nov;18(5):1051-9.

PMID:
17914554
8.

Prognostic value of xanthine oxidoreductase expression in patients with non-small cell lung cancer.

Kim AW, Batus M, Myint R, Fidler MJ, Basu S, Bonomi P, Faber LP, Wightman SC, Warren WH, McIntire M, Arvanitis LD, Gattuso P, Xu X, Liptay MJ.

Lung Cancer. 2011 Feb;71(2):186-90. doi: 10.1016/j.lungcan.2010.05.006. Epub 2010 Jun 8.

PMID:
20570389
9.

Prognostic significance of stromal metalloproteinase-2 in ovarian adenocarcinoma and its relation to carcinoma progression.

Torng PL, Mao TL, Chan WY, Huang SC, Lin CT.

Gynecol Oncol. 2004 Feb;92(2):559-67.

PMID:
14766248
10.

Ezrin immunoreactivity in relation to survival in serous ovarian carcinoma patients.

Moilanen J, Lassus H, Leminen A, Vaheri A, Bützow R, Carpén O.

Gynecol Oncol. 2003 Aug;90(2):273-81.

PMID:
12893187
11.

Long-term oncological outcomes of ovarian serous carcinomas with psammoma bodies: a novel insight into the molecular pathogenesis of ovarian epithelial carcinoma.

Motohara T, Tashiro H, Miyahara Y, Sakaguchi I, Ohtake H, Katabuchi H.

Cancer Sci. 2010 Jun;101(6):1550-6. doi: 10.1111/j.1349-7006.2010.01556.x. Epub 2010 Mar 10.

12.

Immunohistochemical analysis of possible chemoresistance markers identified by micro-arrays on serous ovarian carcinomas.

Têtu B, Popa I, Bairati I, L'Esperance S, Bachvarova M, Plante M, Harel F, Bachvarov D.

Mod Pathol. 2008 Aug;21(8):1002-10. doi: 10.1038/modpathol.2008.80. Epub 2008 May 23.

13.

Excision repair cross-complementation group 1 protein overexpression as a predictor of poor survival for high-grade serous ovarian adenocarcinoma.

Scheil-Bertram S, Tylus-Schaaf P, du Bois A, Harter P, Oppitz M, Ewald-Riegler N, Fisseler-Eckhoff A.

Gynecol Oncol. 2010 Nov;119(2):325-31. doi: 10.1016/j.ygyno.2010.07.018. Epub 2010 Aug 21.

PMID:
20728204
14.

[Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].

Shao HL, Shen DH, Xue WC, Li Y, Yu YZ.

Zhonghua Fu Chan Ke Za Zhi. 2007 Apr;42(4):227-32. Chinese.

PMID:
17631760
15.

WT1 gene expression as a prognostic marker in advanced serous epithelial ovarian carcinoma: an immunohistochemical study.

Netinatsunthorn W, Hanprasertpong J, Dechsukhum C, Leetanaporn R, Geater A.

BMC Cancer. 2006 Apr 11;6:90.

17.

Prognostic significance of fascin expression in advanced poorly differentiated serous ovarian cancer.

Daponte A, Kostopoulou E, Papandreou CN, Daliani DD, Minas M, Koukoulis G, Messinis IE.

Anticancer Res. 2008 May-Jun;28(3B):1905-10. Erratum in: Anticancer Res. 2010 Jan;30(1):277. Papandreou, C N [added]; Daliani, D D [added].

18.

p53 overexpression is not an independent prognostic factor for patients with primary ovarian epithelial cancer.

Eltabbakh GH, Belinson JL, Kennedy AW, Biscotti CV, Casey G, Tubbs RR, Blumenson LE.

Cancer. 1997 Sep 1;80(5):892-8.

PMID:
9307189
19.

Tissue and serum metalloproteinase (MMP-2) expression in advanced ovarian serous cystoadenocarcinomas: clinical and prognostic implications.

Garzetti GG, Ciavattini A, Lucarini G, Goteri G, de e Nictolis M, Garbisa S, Masiero L, Romanini C, Graziella B.

Anticancer Res. 1995 Nov-Dec;15(6B):2799-804.

PMID:
8669868
20.

Prognostic significance of p53 expression in advanced-stage ovarian serous borderline tumors.

Gershenson DM, Deavers M, Diaz S, Tortolero-Luna G, Miller BE, Bast RC Jr, Mills GB, Silva EG.

Clin Cancer Res. 1999 Dec;5(12):4053-8.

Supplemental Content

Support Center